About Us

Home > About Histogen > Management


Histogen’s Executive Management team has decades of experience in bringing cell-based regenerative products from concept to market. In addition, the Company’s Board of Directors and Scientific Advisors are leaders in the fields of regenerative medicine and global marketing and business operations. Histogen has brought on experienced consultants to advise the team in regulatory, quality and production areas. In 2017, Histogen’s Board of Directors created an Office of the CEO (OTC), a group of executives to lead the Company through its next stages of success. The Office of the CEO consists of Chairman of the Board Dr. Stephen Chang, Dr. Martin Latterich and Mr. Stephen Hill.

Gail K. Naughton, Ph.D., CSO & Founder

Gail K. NaughtonDr. Naughton founded Histogen, Inc. in 2007, and currently serves as Chief Scientific Officer for the Company. She has spent more than 30 years extensively researching the tissue engineering process, holds more than 100 U.S. and foreign patents and has been extensively published in the field.gnaughton@histogeninc.com

Martin Latterich. Ph.D., Vice President of Technical Operations & Member of the OTC

Martin LatterichDr. Latterich is a biotechnology executive with a strong mix of business and academic experience. Currently also serving as CSO of ProterixBio (formerly BioScale), Inc., his past professional affiliations include the Salk Institute as Assistant Professor, Diversa (NASDAQ: VRNM) as Principal Scientist, Illumina (NASDAQ: ILMN) as Director of Proteomics, McGill Medical School and the University of Montreal as Associate Professor, the Proteogenomics Research Institute for Systems Medicine as Professor and the Nicholas Conor Institute as founding CEO and CSO.

Stephen Hill, Vice President / Controller & Member of the OTC

Stephen Hill is a versatile senior-level financial executive with a variety of industry experience including manufacturing, biotech and healthcare technology. He most recently served as Accounting Manager, replacing the CFO, at Dotwork Systems, where he was responsible for a variety of functions including finance, accounting, and strategic advisory on multiple matters. Prior to this, Stephen held positions as Director of Finance for both InTuun System and Aviva Systems Biology Corp, and as a Divisional Controller for Bush Industries, Inc. He holds an MBA, and is formerly a practicing California CPA rising to Audit Manager in a national CPA firm.

Michael P. Zimber, Ph.D., Director of Applied Research

Michael P. ZimberDr. Michael Zimber brings to Histogen over 15 years of diverse experience in the biotechnology and pharmaceutical industry with a multi-disciplinary background in early phase discovery, preclinical development and translational phases of therapeutic development. He began his scientific career studying developmental biology conducting research on tissue pattern formation and amphibian limb regeneration. mzimber@histogeninc.com

Dr. Mark A. Hubka, Director of Clinical Affairs

Dr. Mark A. HubkaDr. Hubka brings more than 25 years of clinical experience from the fields of orthopedics and sports medicine to Histogen. His experience in managed care includes his time as State Director of the largest designated provider network (DPN) in California, focused on worker's compensation. mhubka@histogeninc.com

Eileen Brandt, Director of Corporate Communications

Eileen Naughton BrandtEileen brings more than 5 years of experience in communications and public relations to Histogen. Prior to joining Histogen in 2007, she held positions with Moore Media Relations, Inc., a firm working with high-technology companies throughout the U.S. on various PR projects, with a focus on media relations. Previously, Eileen held positions at San Diego State University's Entrepreneurial Management Center, beginning as a Student Assistant at the San Diego State University and later serving as Program Coordinator. ebrandt@histogeninc.com

Thomas Hubka, Director of Business Operations

Thomas has spent 6 years with Histogen focusing on business development, finance and operations.  He works closely with all facets of the Company to ensure corporate budgeting and forecasting, and has been integral to development of the Company’s cost accounting policies.

Histogen Inc. is a regenerative medicine company based on the commercialization of products manufactured by newborn human cells.
  • Broad range of markets, which are underserved and expected to grow
  • Rich product portfolio
  • Solutions without the use of embryonic stem cells or animal products
© Histogen Inc., CA 92121